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Alzheimer’s disease (AD), the leading cause of dementia of late-life in human, is
a progressive neurodenerative disease associated with age. Extracellular senile
plaques and intracellular neurofibrillary tangles are two major hallmarks of AD
pathology. Mounting evidence demonstrates that accumulation and aggregation of
ȕ-amyloid (Aȕ) in brain play central role in the pathogenesis of AD. Aȕ production,
clearance, aggregation and deposition are differently regulated by apolipoprotein E
(ApoE) isoforms. The transcriptional regulation of apoE is controlled by nuclear
receptors peroxisome proliferator-activated receptor gamma (PPARȖ) and liver X
receptors (LXRs) forming obligate heterodimers with Retinoid X receptors (RXRs).
Interestingly, scientists found that bexarotene, an RXR agonist, increases apoE
production and its lipidation, promote clearance of soluble Aȕ in an apoE-dependent
manner and ameliorates memory deficit in a mouse model of AD. Herein, to identify
novel compounds that can increase apoE levels, we performed a drug screen using a
natural compounds library with a culture system of immortalized astrocytes from
human APOE-TR mice. Furthermore, we discuss the mechanism of increasing apoE
level in vitro and demonstrate the effect of compounds in AD mouse model.
In the present study, we found quercetin and luteolin-7-O-glucoside significantly
increase apoE levels, but the mechanisms of increasing apoE levels are different.
Quercetin doesn’t affect apoE mRNA, ABCA1 and ABCG1 levels. And quercetin
increases apoE protein level through inhibiting apoE degradation and suppresses
cell-associated Aȕ level. In addition, quercetin could significantly increase apoE
protein level and reduce insoluble Aȕ level in the cortex of 5xFAD mice. However,
luteolin-7-O-glucoside significantly increases apoE level not only by promoting apoE
aggregation but also through the LXR/RXR pathway in astrocytes. Our results have
strong implications on exploring a novel class of drug for apoE-targeted AD therapy.
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AD Alzheimer’s dieease 䱯ቄ㥘⎧唈⯵
ApoE Apolipoprotein E 䖭㜲㳻ⲭ E
APP Amyloid Precursor protein ⏰㊹ṧࡽփ㳻ⲭ
$ȕ Amyloid-ȕ ȕ-⏰㊹ṧ㳻ⲭ
Tau Microtubule-associated protein ᗞ㇑⴨ޣ㳻ⲭ
NFT Neurofibrillary Tangles 㓔㔤ॆ㕐㔃
FAD Familly Alzheimer’s disease ᇦ᯿ᙗ AD
Sporadic AD Sporadic Alzheimer’s disease ᮓਁᙗ AD
EOAD Early-onset Alzheimer’s disease ᰙਁᙗ AD
LOAD Late-onset Alzheimer’s disease ᲊਁᙗ AD
BACE ȕ-site APP cleaving enzyme ȕ-ս⛩ APP࠷ࢢ䞦
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GSK-3ȕ Glycogen-synthase kinase-3ȕ ㌆৏ਸᡀ䞦◰䞦-3ȕ
CDK5 Cyclin-dependent kinase-5 㓶㜎ઘᵏ׍䎆ᙗ◰䞦 5
HDL High-density lipoprotein 儈ᇶᓖ㜲㳻ⲭ
VLDL Very-low density lipoprotein ᶱվᇶᓖ㜲㳻ⲭ
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ABCA1 ATP binding cassette A1 protein ATP㔃ਸⴂ䖭㜲㳻ⲭ A1
ABCG1 ATP binding cassette G1 protein ATP㔃ਸⴂ䖭㜲㳻ⲭ G1
PIB Pittsburgh Compound B ३ީ๑ॆਸ⢙ B
LPS Lipopolysaccharides 㜲ཊ㌆
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